AstraZeneca Sales, Profit Outshine Estimates on Cancer Drugs
AstraZeneca Plc reported better-than-expected profit and revenue in the fourth quarter and forecast further gains, helped by ...
AstraZeneca reports better than expected profit on higher cancer drug sales
Earnings per share excluding some items surged to $2.09, Astra said Thursday, higher than the $2.04 estimated by analysts ...
verywellhealth6h
A New 'Missile' Drug Is Approved To Treat the Most Common Breast Cancer Type
The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...
AstraZeneca Plc (AZN) Q4 2024 Earnings Call Transcript
Welcome, ladies and gentlemen, to AstraZeneca's full-year and Q4 2024 results conference call for investors and analysts.
Investing21h
AstraZeneca’s Q4 revenue jumps on strong Oncology and Cardiovascular drug sales
In addition to revenue growth, AstraZeneca's core earnings per share climbed 44% to $2.09. Research and development spending ...
precisionmedicineonline8h
AstraZeneca Optimistic About Phase III Capivasertib Data in 2025, Reports Strong Q4 Product Growth
If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.
AstraZeneca ‘very disappointed’ after ditching £450m Liverpool vaccine site
The boss of drugmaker AstraZeneca has said he was “very disappointed” with the firm’s move to scrap plans for a £450 million ...
STAT14h
AstraZeneca offers some reassurance on China challenges
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...